Over 1 Year Ago
0 Min Read

RCKT up 10%. Is there a catalyst?

Shares of Rocket Pharmaceuticals Inc (RCKT) are trading 8% higher at a price of $15.185 at the time of this writing. While the Health Care sector is having a green day in general, the company is outperforming it's peers. The market is undergoing a small move (0.42, which is unlikely to be the catalyst for the stock's movement.

- Rocket's gene therapy for heart disease is showing promise in children and adults in a phase 1 trial
- The trial is testing the safety and effectiveness of the therapy
- The results are encouraging so far

Rocket Pharmaceuticals Inc has been trading between a 52-week high of $36.87 and a 52-week low of $7.57. The stock has a market cap of $1 Billion.

Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases.


Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Business Wire 09-30-22

Rocket Pharmaceuticals Inc. (RCKT) can beat the pack with these strategies
US Post News 09-27-22

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
Business Wire 09-27-22

The M&A Class Action Firm Announces an Investigation of Renovacor, Inc. - RCKT
Kwhen Finance 09-22-22

Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Benzinga 09-21-22